Ribociclib plus letrozole alters the immune subset composition in older (≥70 yrs.) patients with HR+/HER2-metastatic breast cancer

被引：0
|
作者：
Lambrechts, Yentl
Hatse, Sigrid
Kenis, Cindy
Decoster, Lore
de Azambuja, Evandro
Jerusalem, Guy
Neven, Patrick
Dal Lago, Lissandra
Denys, Hannelore
Vuylsteke, Peter
Cornelis, Frank
Punie, Kevin
Floris, Giuseppe
Desmedt, Christine
Laenen, Annouschka
Ponde, Noam
Wildiers, Hans
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-01-29
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-29
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Identifying Drivers of First-Line HR+/HER2-Metastatic Breast Cancer Treatment Choices
    Brufsky, Adam M.
    Maculaitis, Martine C.
    Kopenhafer, Lewis
    Olsen, Patrick
    Cha, Ashley S.
    Arruda, Lillian Shahied
    Heck, Wendy
    Kurosky, Samantha K.
    CANCER RESEARCH, 2023, 83 (05)
  • [42] Patient and treatment characteristics in HR+/HER2-metastatic breast cancer in a real-life setting
    Karadurmus, Nuri
    Sendur, Mehmet Ali Nahit
    Cil, Timucin
    Oksuzoglu, Omur Berna Cakmak
    Arslan, Cagatay
    Harputluoglu, Hakan
    Goksu, Sema Sezgin
    Ozturk, Banu
    MevludeInanc
    Cubukcu, Erdem
    Demirci, Umut
    Erdem, Dilek
    Cihan, Sener
    Tural, Deniz
    Dumludag, Aysegul
    Yilmaz, Funda
    Avsar, Esin
    Sonusen, Sermin Dinc
    Ozturk, Ozge Fulya
    Aver, Birkan
    Kaplan, Muhammet Ali
    CANCER RESEARCH, 2023, 83 (05)
  • [43] The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2-metastatic breast cancer
    Ovcaricek, Tanja
    Matos, Erika
    Borstnar, Simona
    Ribnikar, Domen
    Kuhar, Cvetka Grasic
    Cankar, Kaja
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [44] Ribociclib plus letrozole in patients with HR+, HER2-advanced breast cancer: Safety analysis of the phase 3b CompLEEment-1 trial
    Lu, Janice
    Cottu, Paul
    Martin, Miguel
    Zamagni, Claudio
    Zhou, Katie
    Wu, Jiwen
    Ankrah, Nii
    De Laurentiis, Michelino
    CANCER RESEARCH, 2020, 80 (04)
  • [45] Dosing Patterns and Economic Burden of Palbociclib Drug Wastage in HR+/HER2-Metastatic Breast Cancer
    Dalal, Anand A.
    Gagnon-Sanschagrin, Patrick
    Burne, Rebecca
    Guerin, Annie
    Gauthier, Genevieve
    Small, Tania
    Niravath, Polly
    ADVANCES IN THERAPY, 2018, 35 (06) : 768 - 778
  • [46] Treatment patterns and characteristics of postmenopausal women with HR+/HER2-metastatic breast cancer receiving everolimus
    Vekeman, Francis
    Hao, Yanni
    Cheng, Wendy Y.
    Fortier, Jonathan
    Robitaille, Marie-Noelle
    Duh, Mei Sheng
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 114 - 115
  • [47] Ribociclib plus letrozole vs placebo plus letrozole in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) and a high disease burden
    Verma, S.
    Gil-Gil, M.
    Hegg, R.
    Wheatley-Price, P.
    Kattan, J.
    Bourgeois, H.
    Sutradhar, S.
    Miller, M.
    Campone, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [48] Treatment patterns and resource utilization among patients with HR+/HER2-metastatic breast cancer in a privately insured US population
    Goyal, R. K.
    Carter, G. C.
    Nagar, S. N.
    Smyth, E. N.
    Price, G. L.
    Huang, Y-J
    Bromund, J. L.
    Li, L.
    Schilder, J. M.
    Davis, K. L.
    Kaye, J. A.
    CANCER RESEARCH, 2017, 77
  • [49] Abemaciclib for treating patients with HR+/HER2-metastatic breast cancer: a real-world study in France, Italy and Spain
    Blancas, Isabel
    Grosjean, Jessica
    Pedersini, Rebecca
    Buzzoni, Carlotta
    Sleilaty, Ghassan
    Molero, Alberto
    Tamma, Antonella
    Chouaki, Nadia
    Atienza, Manuel
    Emde, Anna
    Siddi, Sara
    Bayona, Rodrigo Sanchez
    Del Mastro, Lucia
    Fakhouri, Walid
    FUTURE ONCOLOGY, 2024, 20 (31) : 2371 - 2384
  • [50] Genomic Profiling of Premenopausal HR+ and HER2-Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib
    Bardia, Aditya
    Su, Fei
    Solovieff, Nadia
    Im, Seock-Ah
    Sohn, Joohyuk
    Lee, Keun Seok
    Campos-Gomez, Saul
    Jung, Kyung Hae
    Colleoni, Marco
    Villanueva Vazquez, Rafael
    Franke, Fabio
    Hurvitz, Sara
    Harbeck, Nadia
    Chow, Louis
    Taran, Tetiana
    Lorenc, Karen Rodriguez
    Babbar, Naveen
    Tripathy, Debu
    Lu, Yen-Shen
    JCO PRECISION ONCOLOGY, 2021, 5 : 1408 - 1420
12345